Biosimulation Market Focusing On The Basis Of Product, Application, End-Use, Region And Forecast 2030 : Grand View Research Inc.

San Francisco, 8 Sep 2022: The Report Biosimulation Market Size, Share & Trends Analysis Report By Product (Software, Services), By Application (Drug Development, Drug Discovery), By End Use, By Region, And Segment Forecasts, 2022 – 2030

The global biosimulation market size is expected to reach USD 9.95 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 16.9% from 2022 to 2030. The key factors fueling the market growth include the increasing incidence of chronic diseases, increase in healthcare digitization, and usage of biosimulation solutions in clinical trials and research.

The need for drug discovery and development amidst the prevalence of acute and chronic diseases has increased the allocation of funds for R&D activities, which has propelled the adoption of biosimulation solutions. In addition, a high drug attrition rate leads to an increase in the cost of clinical trials, which is expected to drive the clinical urgency to incorporate in silico biology approach. This approach significantly reduces the probability of drug failure by predicting biological interactions, thereby reducing overall costs.

A rise in drug relapse rates, drug resistance cases, and the limited availability of drugs to treat diseases such as AIDS have led to high clinical urgency for the adoption of biosimulation in applications such as drug development and drug discovery.

The COVID-19 pandemic also had a significant impact on the market growth. Simulations Plus, for instance, launched the StrategiesPlus COVID-19 ACT Program in March 2020 for speeding consulting assistance to any organization involved in COVID-19 research. The company declared that as of November 2020, its business was not materially adversely affected. However, the continuing spread of COVID-19 and the measures taken by governments of affected countries are likely to disrupt the supply chain and adversely impact its business and financial performance.

Surging demand for biosimulation software and services can also be attributed to their higher cost-efficiency. Biosimulation solutions enable cost-effective prediction of toxicity, adverse reactions, and efficacy of investigational drugs during the early stages of product development, thus limiting the probability of drug relapse and adverse events at later stages.

Market players are investing in many strategic initiatives, such as acquisitions, mergers, partnerships, and product launches, to maintain a competitive edge in the market. For instance, in January 2022, Simulations Plus Inc. collaborated with an animal health company for validating current animal physiologically based pharmacokinetic (PBPK) models. With this funded collaboration, the company aimed to add a critical new species to its GastroPlus platform. Moreover, in November 2021, Yokogawa Electric Corporation acquired Insilico Biotechnology AG, a Germany-based company that develops and provides bioprocess software and services.

Access Research Report of Biosimulation Market @ https://www.grandviewresearch.com/industry-analysis/biosimulation-industry

Biosimulation Market Report Highlights

• By product, software dominated the market in 2021. This can be attributed to the availability of a wide range of application-specific software that suits research requirements. Furthermore, biosimulation software is being used in clinical trials and it also eases modeling and targets drug identification
• The drug development application segment accounted for the largest revenue share of more than 55.0% in 2021
• By end-use, pharmaceutical and biotechnology companies held the largest revenue share in 2021 due to the increasing strategic initiatives
• North America grabbed the largest revenue share of over 45.0% in 2021. The presence of a favorable reimbursement framework (especially post the implementation of the Affordable Care Act) and sophisticated healthcare infrastructure are expected to drive the regional market over the forecast period
• The Asia Pacific region is expected to grow significantly during the forecast period owing to the increase in the number of CROs, growth in spending on healthcare IT, and rapidly evolving healthcare infrastructure

List of Key Players of the Biosimulation Market

• Certara, USA
• Dassault Systemes
• Advanced Chemistry Development
• Simulation Plus
• Schrodinger, Inc.
• Chemical Computing Group ULC
• Physiomics Plc
• Rosa & Co. LLC
• BioSimulation Consulting Inc.
• Genedata AG
• Instem Group of Companies
• PPD, Inc.
• Yokogawa Insilico Biotechnology GmbH
• Immunetrics

Access Press Release of Biosimulation Market @ https://www.grandviewresearch.com/press-release/global-biosimulation-market

Biosimulation Market Projected To Expand At A CAGR 15.9% For The Forecast Period From 2021 To 2028: Grand View Research Inc.

San Francisco, 4 Feb 2022: The Report Biosimulation Market Size, Share & Trends Analysis Report By Product (Software, Services), By Application (Drug Development, Drug Discovery), By End Use, By Region, And Segment Forecasts, 2021 – 2028

The global biosimulation market size is anticipated to reach USD 6.83 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 15.9% from 2021 to 2028. The key factors fueling the market growth include the increasing incidence of chronic diseases, increase in healthcare digitization, and usage of biosimulation solutions in clinical trials and research.

The need for drug discovery and development amidst the prevalence of acute and chronic diseases has resulted in an increase in the allocation of funds for R&D activities, which has propelled the adoption of biosimulation solutions. In addition, a high drug attrition rate leads to an increase in the cost of clinical trials, which is expected to drive the clinical urgency to incorporate in silico biology approach. This approach significantly reduces the probability of drug failure by predicting biological interactions, thereby reducing the overall costs.

Arise in drug relapse rates, drug resistance cases, and limited availability of drugs to treat diseases such as AIDS have led to high clinical urgency for the adoption of biosimulation in applications, such as drug development and drug discovery.

The COVID-19 pandemic also had a significant impact on the market. Simulations Plus, for instance, launched the StrategiesPlus COVID-19 ACT Program in March 2020 for speeding consulting assistance to any organization involved in the COVID-19 research. As of November 2020, the company declared that its business was not materially adversely affected. However, the continuing spread of COVID-19 and the measures taken by the governments of the affected countries are likely to disrupt the supply chain and adversely impact its business and financial performance.

Surging demand for biosimulation software and services can also be attributed to their higher cost-efficiency. Biosimulation solutions enable cost-effective prediction of toxicity, adverse reactions, and efficacy of investigational drugs during early stages of product development, thus limiting the probability of drug relapse and adverse events at later stages.

Access Research Report of Biosimulation Market @ https://www.grandviewresearch.com/industry-analysis/biosimulation-industry

Biosimulation Market Report Highlights

• In terms of product, software dominated the market in 2020. This can be attributed to the availability of a wide range of application-specific software that suits research requirements. Furthermore, biosimulation software is being used in clinical trials and it also eases modeling and target drug identification
• By application, the drug development segment accounted for the largest share in 2020
• Based on end use, pharmaceutical and biotechnology companies dominated the market in 2020 due to increasing strategic initiatives
• North America grabbed the largest share in 2020. The presence of a favorable reimbursement framework (especially post the implementation of the Affordable Care Act) and sophisticated healthcare infrastructure is expected to drive the North American market over the forecast period
• Asia Pacific is expected to grow significantly during the forecast period owing to the increase in the number of CROs, growth in spending on healthcare IT, and rapidly evolving healthcare infrastructure

List of Key Players of Biosimulation Market

• Certara
• DassaultSystemes
• Advanced Chemistry Development
• Simulation Plus
• Schrodinger, Inc.
• Chemical Computing Group ULC
• PhysiomicsPlc
• Rosa & Co. LLC
• BioSimulation Consulting Inc.
• Genedata AG
• Instem Group of Companies
• PPD, Inc. (Evidera)
• Insilico Biotechnology AG
• Immunetrics

Access Press Release of Biosimulation Market @ https://www.grandviewresearch.com/press-release/global-biosimulation-market

Biosimulation Market is Predicted to Observe a Tremendous Growth, With a CAGR of 15.9% From 2021 To 2028: Grand View Research Inc.

San Francisco, 27 Aug 2021: The Report Biosimulation Market Size, Share & Trends Analysis Report By Product (Software, Services), By Application (Drug Development, Drug Discovery), By End Use, By Region, And Segment Forecasts, 2021 – 2028

The global biosimulation market size is anticipated to reach USD 6.83 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 15.9% from 2021 to 2028. The key factors fueling the market growth include the increasing incidence of chronic diseases, increase in healthcare digitization, and usage of biosimulation solutions in clinical trials and research.

The need for drug discovery and development amidst the prevalence of acute and chronic diseases has resulted in an increase in the allocation of funds for R&D activities, which has propelled the adoption of biosimulation solutions. In addition, a high drug attrition rate leads to an increase in the cost of clinical trials, which is expected to drive the clinical urgency to incorporate in silico biology approach. This approach significantly reduces the probability of drug failure by predicting biological interactions, thereby reducing the overall costs.

Arise in drug relapse rates, drug resistance cases, and limited availability of drugs to treat diseases such as AIDS have led to high clinical urgency for the adoption of biosimulation in applications, such as drug development and drug discovery.

The COVID-19 pandemic also had a significant impact on the market. Simulations Plus, for instance, launched the StrategiesPlus COVID-19 ACT Program in March 2020 for speeding consulting assistance to any organization involved in the COVID-19 research. As of November 2020, the company declared that its business was not materially adversely affected. However, the continuing spread of COVID-19 and the measures taken by the governments of the affected countries are likely to disrupt the supply chain and adversely impact its business and financial performance.

Surging demand for biosimulation software and services can also be attributed to their higher cost-efficiency. Biosimulation solutions enable cost-effective prediction of toxicity, adverse reactions, and efficacy of investigational drugs during early stages of product development, thus limiting the probability of drug relapse and adverse events at later stages.

Access Research Report of Biosimulation Market @ https://www.grandviewresearch.com/industry-analysis/biosimulation-industry

Biosimulation Market Report Highlights

• In terms of product, software dominated the market in 2020. This can be attributed to the availability of a wide range of application-specific software that suits research requirements. Furthermore, biosimulation software is being used in clinical trials and it also eases modeling and target drug identification
• By application, the drug development segment accounted for the largest share in 2020
• Based on end use, pharmaceutical and biotechnology companies dominated the market in 2020 due to increasing strategic initiatives
• North America grabbed the largest share in 2020. The presence of a favorable reimbursement framework (especially post the implementation of the Affordable Care Act) and sophisticated healthcare infrastructure is expected to drive the North American market over the forecast period
• Asia Pacific is expected to grow significantly during the forecast period owing to the increase in the number of CROs, growth in spending on healthcare IT, and rapidly evolving healthcare infrastructure

List of Key Players of Biosimulation Market

• Certara
• DassaultSystemes
• Advanced Chemistry Development
• Simulation Plus
• Schrodinger, Inc.
• Chemical Computing Group ULC
• PhysiomicsPlc
• Rosa & Co. LLC
• BioSimulation Consulting Inc.
• Genedata AG
• Instem Group of Companies
• PPD, Inc. (Evidera)
• Insilico Biotechnology AG
• Immunetrics

Access Press Release of Biosimulation Market @ https://www.grandviewresearch.com/press-release/global-biosimulation-market

Biosimulation Market Expected To Witness A Substantial Growth Of USD 3.77 Billion By 2024: Grand View Research Inc.

San Francisco, 2 Sep 2020: The Report Biosimulation Market Size, Share & Trend Analysis Report By Product (Software, Services), By Application (Drug, Development, Discovery), By End-use, By Region, Vendor Landscape, And Segment Forecasts, 2018 – 2024

The global biosimulation market size is expected to reach USD 3.77 billion by 2024, according to a new report by Grand View Research, Inc., registering a CAGR of 15.4% during the forecast period. Soaring need for advanced generation therapeutics owing to the growing prevalence of chronic diseases, such as cancer and diabetes, is stoking the growth of the biosimulation market.

Moreover, the rising geriatric population worldwide is playing an imperative role in the growth of the market. Aged people are highly susceptible to chronic diseases, which is augmenting the need for highly efficacious drugs. In addition, a growing number of drug resistance cases, high drug relapse rates, and limited availability drugs to treat diseases such as AIDS are leading to high clinical urgency for the adoption of biosimulation in applications such as drug development and drug discovery.

Surging demand for biosimulation software and services can also be attributed to their higher cost-efficiency. This cost efficiency is a result of ability to predict toxicity, adverse reactions, and efficacy of investigational drugs during early stages of product development, thus limiting the probability of drug relapse & adverse events at later stages.

Access Research Report of Biosimulation Market @ https://www.grandviewresearch.com/industry-analysis/biosimulation-industry

Biosimulation Market Report Highlights

• Software accounted for the largest share of the product segment in 2015 owing to growing adoption in personalized medicine resulting in improved patient outcomes
• The services segment is expected to exhibit growth at a significant CAGR as a consequence of rising inclination of the big pharmaceutical companies to outsource their biosimulation process so as to reduce the overall cost
• The drug discovery segment is predicted to witness a lucrative CAGR throughout the forecast period owing to the elimination of probable drug failures and prediction of unfavorable drug interactions
• Drug development accounted for the largest share owing to growing usage of in silico software by major pharmaceutical & biotechnology companies for increased drug efficacy of their existing products by identification and evaluation of optimal synergistic combinations & dosage forms
• In 2015, the pharmaceutical and biotechnology companies held a substantial share owing to growing efforts to develop better treatment options at a cheaper and faster rate through in silico biology models
• Academic research institutes are anticipated to grow at consistent rate owing to the presence of various academic research groups involved in complex biological systems studies that use computer models, such as by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• In 2015, North America accounted for the majority share of the overall market as a result of increased usage of in silico models by regulatory authorities to ensure patient safety
• Asia Pacific is predicted to spearhead the market as a consequence of increasing outsourcing research activities across this region
• Key players are deploying collaborative strategies and expansion of product portfolio to capture a large share. For instance, in April 2016, Simulation Plus, Inc. introduced DDDPlus Version 5.0, an in-vitro dissolution experiment software that helps researchers in study of different drug dosage forms 

Browse more reports of this category by Grand View Research at: https://www.grandviewresearch.com/industry/healthcare-it

Grand View Research has segmented the global biosimulation market report on the basis of product, application, end-use, and region:

Biosimulation Product Outlook (Revenue, USD Million, 2013 – 2024)

• Software
• Services
  • In-house
  • Contract

Biosimulation Application Outlook (Revenue, USD Million, 2013 – 2024)

• Drug Development
• Drug Discovery
• Others

Biosimulation End-use Outlook (Revenue, USD Million, 2013 – 2024)

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Regulatory Authorities
• Academic Research Institutes

Biosimulation Regional Outlook (Revenue, USD Million, 2013 – 2024)

• North America
• Europe
• Asia Pacific
• Middle East & Africa
• Latin America

Access Press Release of Biosimulation Market @ https://www.grandviewresearch.com/press-release/global-biosimulation-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information:www.grandviewresearch.com

Biosimulation Market Insights , Business Opportunities, Current Trends and Forecast 2024: Grand View Research Inc.

San Francisco, 2 January 2020: The Report Biosimulation Market Size, Share & Trend Analysis Report By Product (Software, Services), By Application (Drug, Development, Discovery), By End-use, By Region, Vendor Landscape, And Segment Forecasts, 2018 – 2024

The global biosimulation market size is expected to reach USD 3.77 billion by 2024, according to a new report by Grand View Research, Inc., registering a CAGR of 15.4% during the forecast period. Soaring need for advanced generation therapeutics owing to growing prevalence of chronic diseases, such as cancer and diabetes, is stoking the growth of the biosimulation market.

Moreover, widening base of geriatric population worldwide is playing an imperative role in the growth of the market. Aged people are highly susceptible to chronic diseases, which is augmenting the need for highly efficacious drugs. In addition, growing number of drug resistance cases, high drug relapse rate, and limited availability drugs to treat diseases such as AIDS are leading to high clinical urgency for adoption of biosimulation in applications such as drug development and drug discovery.

Surging demand for biosimulation software and services can also be attributed to their higher cost efficiency. This cost efficiency is a result of ability to predict toxicity, adverse reactions, and efficacy of investigational drugs during early stages of product development, thus limiting the probability of drug relapse & adverse events at later stages.

Access Research Report of Biosimulation Market @ https://www.grandviewresearch.com/industry-analysis/biosimulation-industry

Further Key Findings from the Report Suggest:

• Software accounted for the largest share of the product segment in 2015 owing to growing adoption in personalized medicine resulting in improved patient outcomes
• The services segment is expected to exhibit growth at a significant CAGR as a consequence of rising inclination of the big pharmaceutical companies to outsource their biosimulation process so as to reduce the overall cost
• The drug discovery segment is predicted to witness a lucrative CAGR throughout the forecast period owing to elimination of probable drug failures and prediction of unfavorable drug interactions
• Drug development accounted for the largest share owing to growing usage of in silico software by major pharmaceutical & biotechnology companies for increased drug efficacy of their existing products by identification and evaluation of optimal synergistic combinations & dosage forms
• In 2015, the pharmaceutical and biotechnology companies held a substantial share owing to growing efforts to develop better treatment options at a cheaper and faster rate through in silico biology models
• Academic research institutes are anticipated to grow at consistent rate owing to presence of various academic research groups involved in complex biological systems studies that use computer models, such as by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• In 2015, North America accounted for majority share of overall market as a result of increased usage of in silico models by regulatory authorities to ensure patient safety
• Asia Pacific is predicted to spearhead the market as a consequence of increasing outsourcing research activities across this region
• Key players are deploying collaborative strategies and expansion of product portfolio to capture a large share. For instance, in April 2016, Simulation Plus, Inc. introduced DDDPlus Version 5.0, an in-vitro dissolution experiment software that helps researchers in study of different drug dosage forms

Browse more reports of this category by Grand View Research at: https://www.grandviewresearch.com/industry/healthcare-it

Grand View Research has segmented the global biosimulation market report on the basis of product, application, end-use, and region:

Biosimulation Product Outlook (Revenue, USD Million, 2013 – 2024)

• Software
• Services
  • In-house
  • Contract

Biosimulation Application Outlook (Revenue, USD Million, 2013 – 2024)

• Drug Development
• Drug Discovery
• Others

Biosimulation End-use Outlook (Revenue, USD Million, 2013 – 2024)

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Regulatory Authorities
• Academic Research Institutes

Biosimulation Regional Outlook (Revenue, USD Million, 2013 – 2024)

• North America
• Europe
• Asia Pacific
• Middle East & Africa
• Latin America

Access Press Release of Biosimulation Market @ https://www.grandviewresearch.com/press-release/global-biosimulation-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Biosimulation Market 2018 Insights Business Opportunities, Current Trends and Forecast 2024 : Grand View Research Inc.

San Francisco, 29 April 2019: The Report Biosimulation Market Size, Share & Trend Analysis Report By Product (Software, Services), By Application (Drug, Development, Discovery), By End-use, By Region, Vendor Landscape, And Segment Forecasts, 2018 – 2024

The global Biosimulation Market size is expected to reach USD 3.77 billion by 2024, according to a new report by Grand View Research, Inc., registering a CAGR of 15.4% during the forecast period. Soaring need for advanced generation therapeutics owing to growing prevalence of chronic diseases, such as cancer and diabetes, is stoking the growth of the biosimulation market.

Moreover, widening base of geriatric population worldwide is playing an imperative role in the growth of the market. Aged people are highly susceptible to chronic diseases, which is augmenting the need for highly efficacious drugs. In addition, growing number of drug resistance cases, high drug relapse rate, and limited availability drugs to treat diseases such as AIDS are leading to high clinical urgency for adoption of biosimulation in applications such as drug development and drug discovery.

Surging demand for biosimulation software and services can also be attributed to their higher cost efficiency. This cost efficiency is a result of ability to predict toxicity, adverse reactions, and efficacy of investigational drugs during early stages of product development, thus limiting the probability of drug relapse & adverse events at later stages.

Access Research Report of Biosimulation Market @ www.grandviewresearch.com/industry-analysis/biosimulation-industry

Further Key Findings from the Report Suggest:

• Software accounted for the largest share of the product segment in 2015 owing to growing adoption in personalized medicine resulting in improved patient outcomes
• The services segment is expected to exhibit growth at a significant CAGR as a consequence of rising inclination of the big pharmaceutical companies to outsource their biosimulation process so as to reduce the overall cost
• The drug discovery segment is predicted to witness a lucrative CAGR throughout the forecast period owing to elimination of probable drug failures and prediction of unfavorable drug interactions
• Drug development accounted for the largest share owing to growing usage of in silico software by major pharmaceutical & biotechnology companies for increased drug efficacy of their existing products by identification and evaluation of optimal synergistic combinations & dosage forms
• In 2015, the pharmaceutical and biotechnology companies held a substantial share owing to growing efforts to develop better treatment options at a cheaper and faster rate through in silico biology models
• Academic research institutes are anticipated to grow at consistent rate owing to presence of various academic research groups involved in complex biological systems studies that use computer models, such as by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• In 2015, North America accounted for majority share of overall market as a result of increased usage of in silico models by regulatory authorities to ensure patient safety
• Asia Pacific is predicted to spearhead the market as a consequence of increasing outsourcing research activities across this region
• Key players are deploying collaborative strategies and expansion of product portfolio to capture a large share. For instance, in April 2016, Simulation Plus, Inc. introduced DDDPlus Version 5.0, an in-vitro dissolution experiment software that helps researchers in study of different drug dosage forms.

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/healthcare-it

Grand View Research has segmented the global biosimulation market report on the basis of product, application, end-use, and region:

Biosimulation Product Outlook (Revenue, USD Million, 2013 – 2024)

• Software
• Services
  • In-house
  • Contract

Biosimulation Application Outlook (Revenue, USD Million, 2013 – 2024)

• Drug Development
• Drug Discovery
• Others

Biosimulation End-use Outlook (Revenue, USD Million, 2013 – 2024)

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Regulatory Authorities
• Academic Research Institutes

Biosimulation Regional Outlook (Revenue, USD Million, 2013 – 2024)

• North America
• Europe
• Asia Pacific
• Middle East & Africa
• Latin America

Access Press Release of Biosimulation Market @ www.grandviewresearch.com/press-release/global-biosimulation-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com